To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient

Summary

A Multi-center, Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1903 in Patients with Gastritis

Timeline

Start

2020-11-25

Primary completion

2021-04-27

Completion

2021-05-10

Outcome

Met primary endpoint

paper CONCLUSIONS: DW1903 of a low-dose PPI was not inferior to DW1903R1 of H2RA. PMID 37309193 ↗

Publications

• Kim JH, Jung HY, Yoo IK, Park SY, Kim JG, Sung JK, Jang JS, Cheon GJ, Kim KO, Kim TO, Lee ST, Cho KB, Chun HJ, Park JJ, Park MI, Jang JY, Jeon SW, Cho JW, Kang DH, Kim GH, Kim JJ, Kim SG, Kim N, Lee YC, Hong SJ, Kim HS, Lee S, Lee SW. Evaluation of the Efficacy and Safety of DW1903 in Patients with Gastritis: A Randomized, Double-Blind, Noninferiority, Multicenter, Phase 3 study. Gut Liver. 2024 Jan 15;18(1):70-76. doi: 10.5009/gnl220446. Epub 2023 Jun 13.

Drugs

Indications